SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): June 11, 2012
TARGETED MEDICAL PHARMA, INC.
|(State or other jurisdiction of incorporation or organization)||(Commission File Number)||(IRS Employer Identification No.)|
2980 BEVERLY GLEN CIRCLE, SUITE 301
LOS ANGELES, CA 90077
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 7.01 Regulation FD Disclosure.
Targeted Medical Pharma, Inc. (the “Company”) is considering a variety of financial options in light of the withdrawal of the registration statement on Form S-1 relating to its initial public offering of common stock on June 5, 2012, including a possible sale of claims receivable. Moreover, since the end of the Company’s last fiscal quarter on March 31, 2012, the Company has received approximately $1,500,000 of additional loans from insiders.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 15, 2012
|TARGETED MEDICAL PHARMA, INC.|
|By: /s/ William E. Shell|
|Name: William E. Shell, MD|
|Chief Executive Officer|